WO2004020042A1 - 温熱治療用発熱体およびその製造方法 - Google Patents
温熱治療用発熱体およびその製造方法 Download PDFInfo
- Publication number
- WO2004020042A1 WO2004020042A1 PCT/JP2003/010882 JP0310882W WO2004020042A1 WO 2004020042 A1 WO2004020042 A1 WO 2004020042A1 JP 0310882 W JP0310882 W JP 0310882W WO 2004020042 A1 WO2004020042 A1 WO 2004020042A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heating element
- fine particles
- hyperthermia
- ferromagnetic layer
- treatment
- Prior art date
Links
- 206010020843 Hyperthermia Diseases 0.000 title claims abstract description 40
- 230000036031 hyperthermia Effects 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 32
- 238000010438 heat treatment Methods 0.000 claims abstract description 147
- 235000014413 iron hydroxide Nutrition 0.000 claims abstract description 34
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 claims abstract description 34
- 230000005381 magnetic domain Effects 0.000 claims abstract description 32
- 239000002245 particle Substances 0.000 claims abstract description 24
- 239000007791 liquid phase Substances 0.000 claims abstract description 13
- 239000003302 ferromagnetic material Substances 0.000 claims abstract description 12
- 230000005294 ferromagnetic effect Effects 0.000 claims description 68
- 239000010419 fine particle Substances 0.000 claims description 65
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 52
- 239000010409 thin film Substances 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 229910044991 metal oxide Inorganic materials 0.000 claims description 21
- 150000004706 metal oxides Chemical class 0.000 claims description 21
- 230000005291 magnetic effect Effects 0.000 claims description 20
- 239000011019 hematite Substances 0.000 claims description 18
- 229910052595 hematite Inorganic materials 0.000 claims description 18
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 13
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 11
- 238000000015 thermotherapy Methods 0.000 claims description 11
- 238000007669 thermal treatment Methods 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000151 deposition Methods 0.000 claims description 6
- 229910052814 silicon oxide Inorganic materials 0.000 claims description 6
- 229910010272 inorganic material Inorganic materials 0.000 claims description 5
- 239000011147 inorganic material Substances 0.000 claims description 5
- 229910000859 α-Fe Inorganic materials 0.000 claims description 5
- 229910001308 Zinc ferrite Inorganic materials 0.000 claims description 4
- 229910052712 strontium Inorganic materials 0.000 claims description 4
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 4
- WGEATSXPYVGFCC-UHFFFAOYSA-N zinc ferrite Chemical compound O=[Zn].O=[Fe]O[Fe]=O WGEATSXPYVGFCC-UHFFFAOYSA-N 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 abstract description 2
- 239000000377 silicon dioxide Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 13
- 239000004005 microsphere Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 235000012239 silicon dioxide Nutrition 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 8
- 229910052742 iron Inorganic materials 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910002588 FeOOH Inorganic materials 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000007771 core particle Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000020169 heat generation Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229910000808 amorphous metal alloy Inorganic materials 0.000 description 3
- 230000003073 embolic effect Effects 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- -1 iron fluoride ions Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000005307 ferromagnetism Effects 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- SHXXPRJOPFJRHA-UHFFFAOYSA-K iron(iii) fluoride Chemical compound F[Fe](F)F SHXXPRJOPFJRHA-UHFFFAOYSA-K 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000004876 x-ray fluorescence Methods 0.000 description 2
- 238000004438 BET method Methods 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000007772 electroless plating Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 239000011029 spinel Substances 0.000 description 1
- 229910052596 spinel Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910003153 β-FeOOH Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
- A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
- C01B33/18—Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/02—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
Definitions
- the present invention relates to a heating element for hyperthermia, which is mainly composed of a ferromagnetic material, and a method for producing the same.
- This heating element for heat treatment can be used for heat treatment of cancer.
- cancer tissue has a biological property that it is more susceptible to heat damage than normal tissue, and in recent years, it has attracted attention as a hyperthermia treatment for cancer that locally heats the tumor. ing.
- Magnetic field lines can reach deep into the body without damaging cells. Therefore, focusing on this, the ferromagnetic microspheres are inserted into the body using a catheter or the like, and the portion in which the ferromagnetic microspheres are embedded is placed in an AC magnetic field, thereby generating heat due to hysteresis loss of the ferromagnetic microspheres. It has been proposed to use it to locally heat the tumor.
- a magnetic composition suitable for hyperthermia a magnetic composition characterized by containing an amorphous alloy and a hydrophilic polymer has been proposed.
- the amorphous alloy includes one or more transition metals of Fe, Ni and Co, one or more semimetals of P, C, Si or B, and Cr and Alternatively, those containing Mo (see, for example, Japanese Patent Application Laid-Open No. 6-245939, hereinafter referred to as Reference 1) are mentioned.
- a magnetosensitive heat generating element mainly containing iron-based oxide fine particles having a relative magnetic permeability of 100 to 2000 has been proposed (for example, Japanese Patent Application Laid-Open No. 11-57031). See, below 2).
- the hydrofluoric acid solution containing F e 3 0 4 only saturation concentration, and the core fine particles were immersed silica glass microspheres, by precipitating a coating containing iron, which reduction Kiri ⁇ air gas
- a method has been proposed to produce microspheres with a diameter of about 25 ⁇ m by heat treatment in the atmosphere. Microspheres are produced by this method consists diameter of about 5 0 nm of F e 3 0 4 crystallites on the surface thereof, that has been also reported that a large number of cracks are generated (e.g., "chemical 52, No. 5, (2001), p38-43 ", hereinafter referred to as Reference 3.).
- the magnetic composition disclosed in Document 1 contains an amorphous alloy.
- Amorphous materials generally show soft magnetism and have small hysteresis loss, so it is unclear whether a sufficient amount of heat can be obtained as a heating element for hyperthermia.
- sensitive ⁇ Netsutai disclosed in the above document 2 as an iron-based oxide fine particles which is a main component, F e 3 0 4, iron oxides, such as .gamma. F e 2 0 3, spinel No description is given of the force S in which the iron-based composite oxide is exemplified, and no specific production method thereof. Further, in the production method disclosed in the above-mentioned Reference 3, as a result of the inventors' additional tests based on the description, the precipitation reaction of iron hydroxide is unstable, and the iron hydroxide layer cannot be deposited properly. It turns out that there are cases.
- the present invention has been made in view of the above circumstances, and has as its object the purpose of generating heat with high heat generation efficiency, obtaining a sufficient calorific value, and being magnetically and chemically stable. And a method for producing the same. Disclosure of the invention
- a first characteristic configuration of the present invention is a heating element for thermotherapy mainly comprising a ferromagnetic layer coated on the outside of nuclear fine particles, wherein the ferromagnetic layer is made of an oxide, and its magnetic domain structure is The structure is formed mainly of at least one of the single magnetic domain and the pseudo single magnetic domain.
- the magnetic domain structure of the ferromagnetic layer constituting the heating element is divided into a single magnetic domain and a quasi-single magnetic domain. If at least one of them is mainly formed, there is no influence of the domain wall, such as the mechanism of magnetization reversal when a magnetic field is applied does not depend on the movement of the domain wall. For this reason, the energy of the magnetic field is not spent on the movement of the domain wall but on the heat generated by the magnetic hysteresis loss, so that the amount of heat generated is large, for example, enough to be implanted in a living body to treat cancer. A large amount of heat can be obtained. In addition, since the ferromagnetic layer is made of an oxide, it is chemically stable.
- a second characteristic configuration of the present invention resides in that the ferromagnetic layer is substantially composed of only ferromagnetic crystal grains chemically bonded to each other.
- the ferromagnetic layer is substantially composed only of crystal grains of the ferromagnetic substance chemically bonded to each other, the proportion of the ferromagnetic substance is large, and thus the calorific value is further increased. Also, since it does not contain one component of an organic binder, it is chemically stable even in a living body.
- a third characteristic configuration of the present invention resides in that the crystal grains have shape anisotropy.
- the shape having a shape anisotropy is a shape other than a spherical shape, and means a substantially rod-like shape such as a cocoon, a spheroid, or a needle.
- a fourth characteristic configuration of the present invention resides in that the ferromagnetic layer is mainly composed of one selected from gamma hematite, magnetite, strontium ferrite, and zinc ferrite.
- the ferromagnetic layer is mainly composed of one selected from gamma hematite, magnetite, strontium ferrite, and zinc ferrite, a heating element for thermotherapy that can be expected to generate a sufficient amount of heat can be easily produced. Can be manufactured.
- the ferromagnetic layer is composed of an inorganic oxide, it is harmless even when implanted in a living body, and is suitable.
- a fifth characteristic configuration of the present invention is that the heating element is spherical or substantially spherical with a diameter of 10 to 200 m.
- the heating element has a diameter of 10 to 200 ⁇ , and is spherical or nearly spherical. Any material is suitable, for example, for being implanted and fixed in a blood vessel of a living body.
- the heating element has a diameter of 10 to 40 ⁇ m, for example, it can be effectively implanted and fixed in a peripheral blood vessel of a living body. For this reason, a heating effect and an embolic effect can be obtained for the tumor, which is preferable.
- a sixth characteristic configuration of the present invention resides in that a volume ratio of the ferromagnetic layer to the core fine particles is 3.5 or more.
- a seventh characteristic configuration of the present invention is that a crack is formed in the ferromagnetic layer, and a maximum width of the crack is 3% or less of a diameter of the heating element.
- the maximum width of a crack generated in the ferromagnetic layer is 3% or less of the diameter of the heating element, even if a crack occurs in the ferromagnetic layer, the crack is small relative to the heating element.
- An eighth characteristic configuration of the present invention is that the core fine particles have an average particle size of 0.1 to 10 im and a variation coefficient of the particle size of 15% or less.
- a ninth feature of the present invention resides in that the core fine particles are formed from silicon oxide.
- the ferromagnetic layer can be formed with good adhesion to the core fine particles by the liquid phase method, and the peeling of the ferromagnetic layer and the occurrence of large cracks can be prevented. be able to. It is also preferable because it is chemically stable.
- a tenth feature of the present invention resides in that a metal oxide thin film is coated on the surface of the heating element.
- the ferromagnetic layer is formed by coating the surface with a metal oxide thin film, the ferromagnetic layer functions as a protective film even if cracks occur in the ferromagnetic layer. Can be prevented. Therefore, when the heating element is implanted in a living body and used for thermal treatment, the ferromagnetic layer is preferably fragmented, and the possibility of moving from the treatment site can be reduced. Further, since this thin film is a metal oxide, it is chemically stable and suitable.
- the eleventh characteristic configuration of the present invention is that the metal oxide thin film is formed of any one of silicon oxide, titanium oxide, gamma hematite, magnetite, and iron hydroxide.
- the metal oxide thin film is formed of any of silicon oxide, titanium oxide, gamma hematite, magnetite, and iron hydroxide, these have biocompatibility, Not rejected and suitable. Further, it is preferable that the metal oxide thin film is formed of gamma magnetite-magnetite because the metal oxide thin film can also contribute to heat generation.
- a 12th feature of the present invention resides in that the metal oxide thin film is porous.
- a drug can be contained in the metal oxide thin film, so that it is possible to perform both heat treatment and treatment with the drug, which is preferable.
- a thirteenth characteristic configuration of the present invention resides in that the heating element for hyperthermia consists of only an inorganic material.
- the heating element for hyperthermia is made of only an inorganic material because it is chemically stable.
- a fifteenth characteristic configuration of the present invention is the heating element, wherein the heating element is placed under an alternating magnetic field of 15.92 to 29.45 [kA / m] at a frequency of 100 kHz.
- the calorific value is between 5 and 30 [W / g].
- the calorific value is 5 to 30 [W / g], it is suitable for hyperthermia treatment and effective hyperthermia treatment can be performed, which is preferable.
- a fifteenth feature of the present invention is that a ferromagnetic material in which a ferromagnetic layer is coated on the outside of the core fine particles.
- a method for producing a heating element for hyperthermia which comprises an active substance as a main material, comprising: performing a deposition treatment of depositing iron hydroxide around the core fine particles by a liquid phase method to form a layer; The heat treatment described above changes the iron hydroxide layer formed around the core fine particles into a ferromagnetic material composed of gamma hematite to form the ferromagnetic layer.
- a precipitation treatment of depositing iron hydroxide around the core fine particles by a liquid phase method to form a layer is performed, so that the core particles are formed around the core fine particles.
- Uniform iron hydroxide can be precipitated.
- a ferromagnetic layer made of gamma hematite can be formed.
- this manufacturing method it is possible to manufacture a heating element for hyperthermia treatment having a ferromagnetic layer whose magnetic domain structure is formed mainly of at least one of a single magnetic domain and a pseudo single magnetic domain.
- a homogeneous ferromagnetic layer can be formed on the core fine particles, and a large number of heating elements for thermotherapy can be economically manufactured.
- the core fine particles have an average particle diameter of 0.1 to 10 ⁇ and a coefficient of variation of the particle diameter of 15% or less. Is the place to use.
- a seventeenth characteristic configuration of the present invention is that, in the above-described manufacturing method, the heating rate in the range of 100 to 500 in the heat treatment is set to 5 minutes or less. That is, by performing such a heat treatment, the stress caused by volume shrinkage caused by the dehydration condensation reaction of the ferromagnetic layer can be suppressed from being concentrated on a specific part, so that the width of the generated crack can be reduced. This is preferable because it can be reduced.
- An eighteenth characteristic configuration of the present invention resides in that, in the above-described manufacturing method, the heating rate is 1 ° C./min or less.
- a nineteenth characteristic configuration of the present invention is the above-described manufacturing method, wherein the heat treatment is performed by putting the core fine particles having the iron hydroxide layer formed therein into a cylindrical drum and rotating the core fine particles. Is to reduce.
- such a heat treatment is preferable because the reduction of the core fine particles having the iron hydroxide layer formed thereon can be uniform.
- a magnetic domain In general, the smallest magnet unit inside a ferromagnetic material is called a magnetic domain.
- a single-domain structure with only one magnetic domain is called a single-domain structure.
- a structure with multiple magnetic domains is called a multi-domain structure.
- a quasi-single magnetic domain is defined as one (2 to 5) magnetic domains in one crystal grain.
- the coefficient of variation is the ratio between the population standard deviation ⁇ of the population and the population mean ⁇ , and is expressed by the following equation.
- Figure 1 is a schematic diagram of a film forming apparatus for forming an iron hydroxide layer
- Figure 2 is a schematic diagram of the reduction furnace.
- FIG. 3 is a diagram in which the outline of the crystal grains constituting the ferromagnetic layer is traced
- FIG. 4 is a schematic cross-sectional view of the heating element for hyperthermia.
- a precipitation treatment was performed in which iron hydroxide was precipitated by a liquid phase method around spherical silica fine particles as an example of core fine particles to form an iron hydroxide layer. Further, by subjecting this to a heat treatment, the ferromagnetic layer was formed by changing the iron hydroxide layer to gamma, thereby producing a heating element for hyperthermia according to the present invention.
- FIG. 1 is a schematic diagram of an apparatus for depositing iron hydroxide on core fine particles by a liquid phase method to form an iron hydroxide layer.
- a is spherical silica fine particles as an example of core fine particles
- b is a treatment liquid
- c is an aqueous boric acid solution as an example of a reaction initiator
- d is ⁇ -FeOOH as an example of iron hydroxide.
- 1 is a vessel
- 2 is a stirrer
- 3 is a pipe for supplying a reaction initiator.
- FIG. 1 shows a state where the spherical silica fine particles a are put into the treatment liquid b, and the treatment liquid b is stirred by the stirrer 2 while dropping the boric acid aqueous solution c.
- the treatment liquid was completely replaced with a new one every 10 days. Then, 30 days later, the microspheres on which 3-FeOOH had been deposited (around the spherical silica fine particles) were taken out of the treatment solution, washed sufficiently, and dried at 100 ° C.
- the microspheres, C0 2 and the volume ratio of H 2 is 70: under a reducing atmosphere of 30 and a mixed gas (total flow rate l O OML / min), of 5 ° CZ min from room temperature The temperature was increased at a speed, and the mixture was heated at 600 ° C. for 1 hour and then allowed to cool.
- Fig. 2 shows the reduction furnace used for this heat treatment.
- the heating furnace 4 a quartz furnace tube 5 arranged at the center of the heating furnace 4, and a cylindrical drum rotating inside the furnace tube 5 are shown. It comprises a rotating tube 7 made of quartz and a motor 8 for rotating the rotating tube 7.
- the rotating tube 7 is rotatably supported at both ends by a plurality of rollers 6.
- a sample chamber 9 is provided inside the rotating tube 7, and a heating heater is provided so as to surround the sample chamber 9. 1 and 2 are provided.
- flange portions 10 and 11 for maintaining a reducing atmosphere are provided at both ends of the reactor core tube 5.
- Reducing gas is introduced from one flange portion 10 and the other flange portion 11 is provided therefrom. It is configured to perform heat treatment in a reducing atmosphere while discharging water.
- a reducing furnace put the microspheres coated with FeOOH into the sample chamber 9 inside the rotating tube 7, seal the flanges 10 and 11, and introduce the reducing gas.
- Heat treatment is performed while rotating the rotary tube 7 as a reducing atmosphere. This is preferable because even reduction can be achieved.
- the heating element for hyperthermia treatment is formed by coating the outside of spherical silica fine particles as core fine particles with a gamma matite layer, and using this layer as a main material.
- the ferromagnetic layer is the main material and occupies at least half of the heating element in volume. Further, it is preferable that the ferromagnetic layer occupies 80% or more of the heating element.
- the ferromagnetic layer of the heating element was confirmed by X-ray diffraction to be mainly composed of gamma hematite. Observation results with a scanning electron microscope (SEM) showed that the heating element had a diameter of about 25 ⁇ m and the thickness of the gamma hematite layer was 8 ⁇ m. Furthermore, the ferromagnetic layer of the heating element was observed to be porous. Then, the magnetic domain structure of the gamma hematite layer of this heating element was examined. The magnetic domain structure was examined using a scanning probe microscope (SPM, manufactured by Seiko Instruments Inc. (SII); SPI370) as a magnetic force microscope (MFM).
- SPM scanning probe microscope
- the size of the magnetic domain was about 40 nm, and it was confirmed that it was a single domain structure.
- the magnetic domain structure in the ferromagnetic layer is composed of a single magnetic domain or a quasi-single magnetic domain, the hysteresis loss is large, which is preferable as a heating element for hyperthermia.
- the magnetic domain observation can also be performed by a spectroscopic magnetic domain observation device, a domain scope, a high magnetic field microcar effect measuring device, or the like.
- the ferromagnetic layer of the heating element was observed with a transmission electron microscope (TEM). From the results, a schematic trace of the outline of the crystal grains constituting the ferromagnetic layer was shown in Fig. 3. Indicated. According to this, it was found that the crystal grains had a cocoon shape and had shape anisotropy.
- the ferromagnetic layer is made of an aggregate of crystal grains having shape anisotropy, because it is magnetically stable.
- the ferromagnetic layer consists essentially of only ferromagnetic grains chemically bonded to each other. This is preferable because it does not contain a binder component and can increase the ratio of the ferromagnetic layer in the heating element for hyperthermia.
- the heating element for hyperthermia can be composed of only inorganic materials, so it has excellent chemical stability.
- a heating element for hyperthermia treatment in which the surface of the heating element was coated with a silicon dioxide thin film as an example of a metal oxide thin film was produced.
- a heating element for hyperthermia treatment whose main material was a gamma hematite layer whose surface was coated with a silicon dioxide thin film, was obtained.
- Fig. 4 shows the cross-sectional structure of the heating element 30 for hyperthermia.
- the heating element 30 is composed of a core particle 10 and a ferromagnetic layer 20 coated therearound. It shows a state of coating with 40.
- Example 3 By the following method, a heating element for hyperthermia treatment was prepared in which the surface of the heating element was coated with an iron hydroxide thin film as an example of a metal oxide thin film.
- this heating element When the composition of this heating element was analyzed by the X-ray fluorescence method, it was found that the surface of the ferromagnetic layer was covered with an iron hydroxide thin film. Further, when the cross section and the surface of the fine particles were observed with a scanning electron microscope, it was found that the thickness of the iron hydroxide thin film was about 500 nm.
- the ferromagnetic layer of the heating element is coated with a silicon dioxide thin film or an iron hydroxide thin film, the ferromagnetic layer can be prevented from being fragmented. You can keep it where you want it. Further, it is preferable because it can have biocompatibility as a heating element for hyperthermia.
- the calorific value of the heating element was measured by the following method.
- Example 2 In an agar aqueous solution obtained by dissolving 0.2 g of agar in 2 Om 1 of hot water at 100.
- the aqueous solution was cooled and solidified to obtain a sample for temperature measurement.
- This sample was fully insulated with Styrofoam, and the frequency was 100 kHz, 23.
- the surface area of the sample prepared in Example 1 (hereinafter referred to as Sample 1) was measured by the BET method. Met.
- the surface area of the silica particles having the same particle size was about 0.2 m 2 g, and Sample 1 had a surface area 10 times or more as compared with those.
- Example 2 In the same manner as in Example 1, microspheres around which 3-Fe e precipitated were obtained. This in a reducing atmosphere of a mixed gas of C0 2 and H 2, the temperature was raised at a rate of 1 ° CZ min from room temperature by allowing to cool with heating for 1 hour at 6 00 ° C, 3- F e OOH was changed to gamma, and a sample 2 consisting of a heating element in which the outside of the spherical silica fine particles was covered with a gamma hematite layer (ferromagnetic layer) was obtained.
- Example 3 In the same manner as in Example 1 and Experimental Example 3, —Fe OOH was obtained around which microspheres were precipitated. This in a reducing atmosphere of a mixed gas of C0 2 and H 2, in 1 0 from room temperature Heating at 600 ° C for 1 hour and allowing it to cool, the / 3—FeOOH changes to gamma, and the outside of the spherical silica fine particles changes to gamma. Sample 3 consisting of a heating element covered with a magnetic layer (ferromagnetic layer) was obtained.
- the heating element for hyperthermia according to the present invention only needs to be a ferromagnetic substance as a main material, and is not limited to the heating element exemplified above.
- the heating element only needs to have at least one of a magnetic domain structure and a single magnetic domain or a pseudo single magnetic domain.
- the ferromagnetic layer only needs to be formed of an aggregate of crystal grains having shape anisotropy of an oxide.
- the crystal grains are not spherical, for example, eyebrows, spheroids,
- the material has shape anisotropy such as a needle shape.
- Such a heating element is manufactured by a method utilizing an equilibrium reaction of iron fluoride ions, as exemplified in Example 1 above, it can be deposited stably and the controllability of the reaction is good.
- the core fine particles can be uniformly coated with the iron hydroxide layer. Further, it is preferable because the diameter of the precipitated crystal is easily controlled.
- the heating element may be manufactured by another liquid phase method such as a method of neutralizing an acidic aqueous solution containing iron ions.
- the heating element is not limited to the method described above.
- the electroless plating method using a solution containing at least iron ions and a reducing agent in addition to gamma hematite and magnetite, Layers composed of various ferrites can be directly formed.
- the heating element is not limited to the gamma hematite illustrated above, but may be any of various ferromagnetic materials.
- the ferromagnetic material may be composed of one or more ferromagnetic materials selected from magnetite, strontium ferrite, and zinc ferrite.
- the metal oxide thin film As the metal oxide thin film, the example made of silicon dioxide was described in Example 2 and the example made of iron hydroxide was described in Example 3, but the metal oxide thin film may be made of titanium oxide or magnetite.
- a metal oxide thin film is composed of these materials, as in the case of silicon dioxide and iron hydroxide, it is possible to prevent the gamma hematite fine particles, which are the heating element, from being fragmented, so that a heating element for hyperthermia treatment is produced. It can be kept at a desired place in the body. Further, the heating element for thermal treatment can be provided with biocompatibility, which is preferable.
- any oxide of various metals other than these, which has chemical stability, can be used as a material for the metal oxide thin film.
- a method for forming the metal oxide thin film a liquid phase method is suitable as exemplified in the above-mentioned embodiment.
- the heating element is not particularly limited as long as it is in the form of fine particles exhibiting ferromagnetism.However, if the heating element is spherical or substantially spherical, it can easily reach a target location in a living body as a heating element for hyperthermia. Preferred.
- the diameter of the heating element is most preferably 10 to 40 m, because the heating element does not pass through the capillaries and stops at the peripheral portion of the artery that feeds the tumor to exert an embolic effect.
- the liquid phase method is preferably applied to spherical or substantially spherical core particles. According to this, a heating element having a uniform particle size can be easily obtained.
- the shape of the core fine particles is not limited to a spherical shape, and any available shape can be used.
- the shape of the fine particles obtained by depositing the iron hydroxide layer obtained by the method described in Example 1 above well reflects the shape of the core fine particles.
- the shape of the heating element after the heat treatment well reflects the shape of the core fine particles. For this reason, when a spherical heating element is to be obtained in consideration of the embolic effect and the like, the shape of the nuclear fine particles may be spherical.
- the core fine particles have a spherical shape with a diameter of 0.1 to 10 ⁇ m and a coefficient of variation of the particle size of 15% or less, because a heating element having a uniform particle size can be obtained.
- the core fine particles were used as the core fine particles.
- the material of the core fine particles is not limited to this as long as it has excellent dispersibility and chemical stability in the treatment solution in which iron hydroxide is precipitated.
- the heating element for hyperthermia is composed entirely of a ferromagnetic material, so that a larger amount of heat can be expected, which is advantageous.
- the core fine particles suitable in the present invention include spherical fine particles made of silicon dioxide or titanium dioxide.
- silicon dioxide fine particles can be easily obtained to have a uniform particle size by a method such as a liquid phase precipitation reaction for neutralizing an aqueous solution of sodium silicate or a sol-gel method using tetraethoxysilane as a starting material. This is preferable because it can be performed.
- the surface of the heating element is not limited to the above-mentioned metal oxide thin film, but may be a bioactive inorganic material having good affinity for bone and human tissue, such as hydroxyapatite.
- the heating element for thermal treatment according to the present invention can be guided to a desired treatment site in the body by moving an external magnetic field.
- Industrial applicability The heating element for thermal treatment according to the present invention can be used for thermal treatment of cancer.
- the present invention is not limited to this, and can be used for locally heating the affected part in various other uses.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Compounds Of Iron (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Magnetic Treatment Devices (AREA)
Abstract
Description
Claims
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/525,856 US20060111763A1 (en) | 2002-08-29 | 2003-08-27 | Heat generating article for hyperthermia and method for preparation thereof |
| GB0502503A GB2408504B (en) | 2002-08-29 | 2003-08-27 | Exothermic elements for hyperthermic treatment, and method of manufacturing same |
| AU2003261775A AU2003261775A1 (en) | 2002-08-29 | 2003-08-27 | Heat generating article for hyperthermia and method for preparation thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002251764 | 2002-08-29 | ||
| JP2002-251764 | 2002-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004020042A1 true WO2004020042A1 (ja) | 2004-03-11 |
Family
ID=31972701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2003/010882 WO2004020042A1 (ja) | 2002-08-29 | 2003-08-27 | 温熱治療用発熱体およびその製造方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20060111763A1 (ja) |
| AU (1) | AU2003261775A1 (ja) |
| GB (1) | GB2408504B (ja) |
| WO (1) | WO2004020042A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| US8430105B2 (en) | 2005-04-28 | 2013-04-30 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010245121A (ja) * | 2009-04-01 | 2010-10-28 | Toshiba Corp | 半導体装置 |
| US20110301401A1 (en) * | 2010-06-08 | 2011-12-08 | Larson Andrew C | Compositions and methods for thermoradiotherapy |
| KR101401988B1 (ko) | 2012-09-07 | 2014-05-30 | 주식회사 동부하이텍 | 반도체 패키지 및 반도체 패키지 형성 방법 |
| CN110436529B (zh) * | 2019-09-08 | 2022-02-15 | 兰州大学第一医院 | 一种可用于磁热疗的Fe3O4纳米棒材料的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06245993A (ja) * | 1993-02-25 | 1994-09-06 | Tomoya Satou | 磁性組成物 |
| JPH08119635A (ja) * | 1994-10-27 | 1996-05-14 | Toda Kogyo Corp | 粒状マグネタイト微粒子粉末の製造法 |
| WO1999033597A1 (fr) * | 1997-12-25 | 1999-07-08 | Nichia Chemical Industries, Ltd. | POUDRE D'ALLIAGE DE Sm-Fe-N ET PROCEDE DE PRODUCTION |
| JPH11191509A (ja) * | 1997-12-25 | 1999-07-13 | Jsr Corp | 磁性粒子、製造方法および診断薬 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1582956A (en) * | 1976-07-30 | 1981-01-21 | Ici Ltd | Composite magnetic particles |
| US5200270A (en) * | 1986-02-25 | 1993-04-06 | Toyo Soda Manufacturing Co., Ltd. | Carrier for a biologically active component for immunoassay or enzymatic reaction |
| US5736349A (en) * | 1989-09-29 | 1998-04-07 | Nippon Paint Co., Ltd. | Magnetic particle and immunoassay using the same |
| DE19638591A1 (de) * | 1996-09-20 | 1998-04-02 | Merck Patent Gmbh | Kugelförmige magnetische Partikel |
| WO2001037721A2 (en) * | 1999-11-22 | 2001-05-31 | The Research Foundation Of State University Of New York | Magnetic nanoparticles for selective therapy |
| US6444162B1 (en) * | 2000-11-27 | 2002-09-03 | The United States Of America As Represented By The United States Department Of Energy | Open-cell glass crystalline porous material |
| US20060111235A1 (en) * | 2002-08-06 | 2006-05-25 | Shinjiro Domi | Method of manufacturing ferromagnetic particle exothermic elements |
| US7318962B2 (en) * | 2005-01-28 | 2008-01-15 | The United States Of America As Represented By The Secretary Of The Navy | Magnetically directed self-assembly of molecular electronic junctions comprising conductively coated ferromagnetic microparticles |
-
2003
- 2003-08-27 WO PCT/JP2003/010882 patent/WO2004020042A1/ja active Application Filing
- 2003-08-27 AU AU2003261775A patent/AU2003261775A1/en not_active Abandoned
- 2003-08-27 US US10/525,856 patent/US20060111763A1/en not_active Abandoned
- 2003-08-27 GB GB0502503A patent/GB2408504B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06245993A (ja) * | 1993-02-25 | 1994-09-06 | Tomoya Satou | 磁性組成物 |
| JPH08119635A (ja) * | 1994-10-27 | 1996-05-14 | Toda Kogyo Corp | 粒状マグネタイト微粒子粉末の製造法 |
| WO1999033597A1 (fr) * | 1997-12-25 | 1999-07-08 | Nichia Chemical Industries, Ltd. | POUDRE D'ALLIAGE DE Sm-Fe-N ET PROCEDE DE PRODUCTION |
| JPH11191509A (ja) * | 1997-12-25 | 1999-07-13 | Jsr Corp | 磁性粒子、製造方法および診断薬 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| US7964123B2 (en) | 2004-06-01 | 2011-06-21 | Boston Scientific Scimed, Inc. | Embolization |
| US8430105B2 (en) | 2005-04-28 | 2013-04-30 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| US9283035B2 (en) | 2005-04-28 | 2016-03-15 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003261775A1 (en) | 2004-03-19 |
| GB2408504B (en) | 2007-01-24 |
| US20060111763A1 (en) | 2006-05-25 |
| GB0502503D0 (en) | 2005-03-16 |
| GB2408504A (en) | 2005-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bretcanu et al. | Synthesis and characterization of coprecipitation-derived ferrimagnetic glass-ceramic | |
| Daboin et al. | Magnetic SiO2-Mn1-xCoxFe2O4 nanocomposites decorated with Au@ Fe3O4 nanoparticles for hyperthermia | |
| WO2006135671A2 (en) | Process for coating a substrate | |
| KR20100074821A (ko) | 가공된 초상자성 마그네시움 페라이트 나노입자의 제조방법 및 그 의학적 용도 | |
| Irfan Hussain et al. | Ferrite nanoparticles for biomedical applications | |
| Ruiz‐Hernández et al. | Glass–glass ceramic thermoseeds for hyperthermic treatment of bone tumors | |
| US20130136696A1 (en) | Metallic nanoparticles with coated shells and applications of same | |
| WO2004020042A1 (ja) | 温熱治療用発熱体およびその製造方法 | |
| Slimani et al. | Morpho-structural and magnetic properties of CoFe2O4/SiO2 nanocomposites: the effect of the molecular coating | |
| Samakosh et al. | Preparation and characterization of core@ shell structures of Glycerin@ Fe3O4, and Al2O3@ Fe3O4 nanoparticles for use in hyperthermia therapy | |
| Miyazaki et al. | In vitro apatite mineralization and heat generation of magnetite-reduced graphene oxide nanocomposites for hyperthermia treatment | |
| JP2004105722A (ja) | 温熱治療用発熱体およびその製造方法 | |
| Sharma et al. | A review on nanoferrites in biomedical applications | |
| JP2010089991A (ja) | 細胞加熱用強磁性粒子およびその水分散体ならびに水分散体の製造方法 | |
| Liu et al. | Sol–gel synthesis of magnetic TiO2 microspheres and characterization of their in vitro heating ability for hyperthermia treatment of cancer | |
| Ehi-Eromosele et al. | Silica functionalized magnesium ferrite nanocomposites for potential biomedical applications: Preparation, characterization and enhanced colloidal stability studies | |
| JP2007325850A (ja) | 温熱治療用マイクロカプセル発熱体及びその製造方法 | |
| Cândido et al. | Chemical and cellular characterization of SPIONs stabilized with sodium citrate | |
| Hayashi et al. | Synthesis of spinel iron oxide nanoparticle/organic hybrid for hyperthermia | |
| Hasan et al. | A critical review on preparation of Fe3O4 magnetic nano-particles and their potential application | |
| Oskoui et al. | Effect of polyethylene glycol 4000 in magnetic properties of 0.2 SiO 2-0.5 FeO-0.3 CaO glass ceramic | |
| JP2008137911A (ja) | 生体親和性の高いアパタイト被覆磁性ナノ粒子 | |
| Akhirudin et al. | Potential of calcium silicate as a coating material on maghemite (γ-Fe2O3) for hyperthermia treatment | |
| JP2829997B2 (ja) | 温熱療法のためのセラミック発熱体の製法 | |
| JP2004107332A (ja) | 強磁性発熱体およびその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003261775 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 0502503 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20030827 |
|
| ENP | Entry into the national phase |
Ref document number: 2006111763 Country of ref document: US Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10525856 Country of ref document: US |
|
| 122 | Ep: pct application non-entry in european phase | ||
| WWP | Wipo information: published in national office |
Ref document number: 10525856 Country of ref document: US |